245 related articles for article (PubMed ID: 15709902)
1. Mechanistic basis of adverse drug reactions: the perils of inappropriate dose schedules.
Shah RR
Expert Opin Drug Saf; 2005 Jan; 4(1):103-28. PubMed ID: 15709902
[TBL] [Abstract][Full Text] [Related]
2. Genetically determined adverse drug reactions involving metabolism.
Lennard MS
Drug Saf; 1993 Jul; 9(1):60-77. PubMed ID: 8347292
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenetic aspects of drug-induced torsade de pointes: potential tool for improving clinical drug development and prescribing.
Shah RR
Drug Saf; 2004; 27(3):145-72. PubMed ID: 14756578
[TBL] [Abstract][Full Text] [Related]
4. The role of reactive drug metabolites in immune-mediated adverse drug reactions.
Hess DA; Rieder MJ
Ann Pharmacother; 1997 Nov; 31(11):1378-87. PubMed ID: 9391694
[TBL] [Abstract][Full Text] [Related]
5. Emerging in vitro tools to evaluate cytochrome P450 and transporter-mediated drug-drug interactions.
Lu C; Liao M; Cohen L; Xia CQ
Curr Drug Discov Technol; 2010 Sep; 7(3):199-222. PubMed ID: 20843292
[TBL] [Abstract][Full Text] [Related]
6. [Therapeutic implications of polymorphisms in cytochromes and drug transporters].
Münster E; Ziegler S; Brunner M
Wien Med Wochenschr; 2005 Feb; 155(3-4):54-8. PubMed ID: 15791777
[TBL] [Abstract][Full Text] [Related]
7. Do women have more adverse drug reactions?
Rademaker M
Am J Clin Dermatol; 2001; 2(6):349-51. PubMed ID: 11770389
[TBL] [Abstract][Full Text] [Related]
8. Hospital admissions resulting from preventable adverse drug reactions.
McDonnell PJ; Jacobs MR
Ann Pharmacother; 2002 Sep; 36(9):1331-6. PubMed ID: 12196047
[TBL] [Abstract][Full Text] [Related]
9. Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer.
Bosch TM; Meijerman I; Beijnen JH; Schellens JH
Clin Pharmacokinet; 2006; 45(3):253-85. PubMed ID: 16509759
[TBL] [Abstract][Full Text] [Related]
10. The role of cisapride in the treatment of pediatric gastroesophageal reflux. The European Society of Paediatric Gastroenterology, Hepatology and Nutrition.
Vandenplas Y; Belli DC; Benatar A; Cadranel S; Cucchiara S; Dupont C; Gottrand F; Hassall E; Heymans HS; Kearns G; Kneepkens CM; Koletzko S; Milla P; Polanco I; Staiano AM
J Pediatr Gastroenterol Nutr; 1999 May; 28(5):518-28. PubMed ID: 10328131
[TBL] [Abstract][Full Text] [Related]
11. Cytochrome p450 polymorphisms in geriatric patients: impact on adverse drug reactions--a pilot study.
Egger T; Dormann H; Ahne G; Pahl A; Runge U; Azaz-Livshits T; Neubert A; Criegee-Rieck M; Gassmann KG; Brune K
Drugs Aging; 2005; 22(3):265-72. PubMed ID: 15813658
[TBL] [Abstract][Full Text] [Related]
12. Important role of proinflammatory cytokines/other endogenous substances in drug-induced hepatotoxicity: depression of drug metabolism during infections/inflammation states, and genetic polymorphisms of drug-metabolizing enzymes/cytokines may markedly contribute to this pathology.
Prandota J
Am J Ther; 2005; 12(3):254-61. PubMed ID: 15891270
[TBL] [Abstract][Full Text] [Related]
13. [From the Viewpoint of Drug Metabolism Research].
Nakajima M
Yakugaku Zasshi; 2017; 137(6):697-705. PubMed ID: 28566576
[TBL] [Abstract][Full Text] [Related]
14. Genetics or environment in drug transport: the case of organic anion transporting polypeptides and adverse drug reactions.
Clarke JD; Cherrington NJ
Expert Opin Drug Metab Toxicol; 2012 Mar; 8(3):349-60. PubMed ID: 22280100
[TBL] [Abstract][Full Text] [Related]
15. Preclinical pharmacokinetics: an approach towards safer and efficacious drugs.
Singh SS
Curr Drug Metab; 2006 Feb; 7(2):165-82. PubMed ID: 16472106
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenetics.
Wolf CR; Smith G
Br Med Bull; 1999; 55(2):366-86. PubMed ID: 10723863
[TBL] [Abstract][Full Text] [Related]
17. Drug interactions with cisapride: clinical implications.
Michalets EL; Williams CR
Clin Pharmacokinet; 2000 Jul; 39(1):49-75. PubMed ID: 10926350
[TBL] [Abstract][Full Text] [Related]
18. An intensive drug monitoring study suggesting possible clinical irrelevance of impaired drug disposition in liver disease.
Naranjo CA; Busto U; Janecek E; Ruiz I; Roach CA; Kaplan K
Br J Clin Pharmacol; 1983 Apr; 15(4):451-8. PubMed ID: 6849781
[TBL] [Abstract][Full Text] [Related]
19. [Clinically relevant adverse drug interactions].
Martin-Facklam M; Haefeli WE
Ther Umsch; 2000 Sep; 57(9):579-83. PubMed ID: 11036439
[TBL] [Abstract][Full Text] [Related]
20. Differences in Toxicological and Pharmacological Responses Mediated by Polymorphic Cytochromes P450 and Related Drug-Metabolizing Enzymes.
Yamazaki H
Chem Res Toxicol; 2017 Jan; 30(1):53-60. PubMed ID: 27750412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
